InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of InflaRx N.V. (NASDAQ:IFRX) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $7.50.

Several analysts recently commented on the stock. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price target (down from $5.00) on shares of InflaRx in a research report on Wednesday, December 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of InflaRx in a report on Tuesday, December 30th. Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a report on Monday, December 29th. Finally, Guggenheim boosted their price objective on shares of InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 10th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC raised its holdings in InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after purchasing an additional 7,616 shares in the last quarter. Woodline Partners LP acquired a new position in InflaRx during the 1st quarter worth approximately $766,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of InflaRx by 158.3% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock worth $118,000 after buying an additional 91,927 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in shares of InflaRx during the 2nd quarter worth approximately $262,000. Finally, Squarepoint Ops LLC lifted its holdings in shares of InflaRx by 29.1% in the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after buying an additional 42,489 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Stock Down 1.2%

IFRX opened at $0.92 on Monday. InflaRx has a 52 week low of $0.71 and a 52 week high of $1.94. The business’s 50 day moving average is $0.97 and its two-hundred day moving average is $1.16. The firm has a market cap of $61.76 million, a price-to-earnings ratio of -1.35 and a beta of 1.48.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.